Fadi El Karak
Overview
Explore the profile of Fadi El Karak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
312
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kourie H, Zouein J, Zalaquett Z, Chebly A, Nasr L, El Karak F, et al.
Clin Res Hepatol Gastroenterol
. 2024 Jul;
48(8):102417.
PMID: 39009221
Background: The absence of KRAS and NRAS gene mutations (RAS wild type) in metastatic colorectal cancer (mCRC), is associated with a good response to targeted therapy with anti-EGFR receptor antibodies....
2.
Soares A, Bourlon M, Wong A, Joshi A, Jardim D, Korbenfeld E, et al.
Clin Genitourin Cancer
. 2024 Jan;
22(2):467-475.
PMID: 38228413
Urothelial carcinoma (UC) is the 10 most common cancer globally with an almost 4 times higher prevalence in men. The main risk factors for development of urothelial carcinoma are advanced...
3.
Ayoub G, Sinan H, Kourie H, Kattan J, Nasr F, El Karak F, et al.
Future Oncol
. 2023 Oct;
19(29):1991-2002.
PMID: 37795707
Chronic lymphocytic leukemia (CLL) is a highly heterogenous hemopathy. Genetic stratification of CLL patients has important prognostic and therapeutic values - mainly immunoglobulin heavy chain variable region gene () mutational...
4.
Chaaya C, Zgheib G, El Karak F
Expert Opin Pharmacother
. 2023 Sep;
24(17):1853-1860.
PMID: 37668151
Introduction: Autophagy is an intracellular process that plays a key role in the cellular homeostasis. Recently, it has been described as a potential therapeutic target in oncology, whether by activating...
5.
Mahrous M, Omar Jebriel A, Allehebi A, Shafik A, El Karak F, Venturini F, et al.
Cureus
. 2023 Jul;
15(7):e41992.
PMID: 37492039
Mesenchymal-epithelial transition exon 14 (METex14) skipping mutations occur in about 3%-4% of patients with non-small cell lung cancer (NSCLC). This is an aggressive subtype associated with poor prognosis. METex14 skipping...
6.
Assi H, Zerdan M, Hodroj M, Khoury M, Naji N, Amhaz G, et al.
Oncotarget
. 2023 May;
14:517-525.
PMID: 37235814
Background: Lung cancer is the number one cause of mortality among all types of cancer worldwide. Its treatment landscape has shifted from the classic chemotherapy alone to newer regimens based...
7.
Ghosn M, Kattan J, El Karak F, Ghanem H, Debs J, Ibrahim K, et al.
Future Oncol
. 2023 May;
19(12):863-872.
PMID: 37194701
Renal cell carcinoma (RCC) management has seen a revolution over the last decades. Six Lebanese oncologists discussed recent updates in RCC management and outlined the challenges and future directions in...
8.
Aoun-Bacha Z, Bitar N, Abi Saleh W, Assi H, Bahous J, Boukhalil P, et al.
Oncol Lett
. 2023 Feb;
25(3):113.
PMID: 36844621
Proper management of stage III non-small cell lung cancer (NSCLC) might result in a cure or patient long-term survival. Management should therefore be preceded by adequate and accurate diagnosis and...
9.
Hajj A, Khoury R, Hachem R, Awad A, Hallit S, Sacre H, et al.
BMC Cancer
. 2022 Sep;
22(1):996.
PMID: 36123640
Background: Breast cancer patients undergoing chemotherapy treatment are at particular risk of experiencing acute cognitive impairment leading to daily challenges in decision-making and reduced quality of life and functional autonomy....
10.
El Gharib K, Macaron W, Kattan J, Salloum M, Farhat F, Smith M, et al.
Curr Probl Cancer
. 2022 Apr;
46(3):100859.
PMID: 35378469
CDK 4/6 inhibitors have been yielding propitious results when with hormone therapy in the management of Her2-negative and hormone-receptor (HR)-positive metastatic breast cancer, palbociclib being one of the first molecules...